SG Americas Securities LLC Acquires 16,982 Shares of TG Therapeutics, Inc. $TGTX

SG Americas Securities LLC lifted its holdings in TG Therapeutics, Inc. (NASDAQ:TGTX) by 27.7% in the fourth quarter, according to its most recent disclosure with the Securities & Exchange Commission. The fund owned 78,357 shares of the biopharmaceutical company’s stock after buying an additional 16,982 shares during the quarter. SG Americas Securities LLC’s holdings in TG Therapeutics were worth $2,336,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds have also added to or reduced their stakes in the stock. Danske Bank A S bought a new stake in TG Therapeutics during the 3rd quarter worth about $25,000. Optiver Holding B.V. raised its stake in shares of TG Therapeutics by 3,485.7% in the third quarter. Optiver Holding B.V. now owns 753 shares of the biopharmaceutical company’s stock worth $27,000 after acquiring an additional 732 shares during the last quarter. Bessemer Group Inc. lifted its position in shares of TG Therapeutics by 117.1% during the third quarter. Bessemer Group Inc. now owns 901 shares of the biopharmaceutical company’s stock worth $33,000 after purchasing an additional 486 shares in the last quarter. Salomon & Ludwin LLC bought a new stake in shares of TG Therapeutics during the third quarter valued at approximately $34,000. Finally, Stone House Investment Management LLC bought a new stake in shares of TG Therapeutics during the third quarter valued at approximately $36,000. Institutional investors and hedge funds own 58.58% of the company’s stock.

TG Therapeutics Stock Performance

Shares of NASDAQ:TGTX opened at $33.53 on Friday. The firm’s 50 day simple moving average is $29.95 and its 200 day simple moving average is $31.52. TG Therapeutics, Inc. has a fifty-two week low of $25.28 and a fifty-two week high of $46.48. The company has a market capitalization of $5.35 billion, a price-to-earnings ratio of 12.10 and a beta of 1.76. The company has a debt-to-equity ratio of 0.38, a current ratio of 4.10 and a quick ratio of 3.29.

TG Therapeutics (NASDAQ:TGTX) last issued its earnings results on Thursday, February 26th. The biopharmaceutical company reported $0.14 EPS for the quarter, missing the consensus estimate of $0.35 by ($0.21). The firm had revenue of $192.57 million during the quarter, compared to the consensus estimate of $192.15 million. TG Therapeutics had a net margin of 72.56% and a return on equity of 101.12%. The firm’s revenue for the quarter was up 78.0% on a year-over-year basis. During the same period in the previous year, the company posted $0.15 EPS. As a group, sell-side analysts forecast that TG Therapeutics, Inc. will post 0.08 earnings per share for the current year.

Analysts Set New Price Targets

Several research firms have issued reports on TGTX. JPMorgan Chase & Co. reduced their price objective on TG Therapeutics from $49.00 to $46.00 and set an “overweight” rating on the stock in a report on Monday, February 2nd. The Goldman Sachs Group raised their target price on shares of TG Therapeutics from $37.00 to $39.00 and gave the company a “neutral” rating in a research note on Thursday, January 15th. Wall Street Zen cut shares of TG Therapeutics from a “buy” rating to a “hold” rating in a research note on Saturday, February 14th. Weiss Ratings reiterated a “hold (c+)” rating on shares of TG Therapeutics in a research report on Monday, December 29th. Finally, Cantor Fitzgerald reissued an “overweight” rating on shares of TG Therapeutics in a research note on Wednesday, January 14th. One investment analyst has rated the stock with a Strong Buy rating, three have assigned a Buy rating and two have assigned a Hold rating to the stock. Based on data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average price target of $50.00.

TG Therapeutics Company Profile

TG Therapeutics, Inc is a clinical‐stage biopharmaceutical company headquartered in New York City that specializes in developing targeted therapies for hematological malignancies and autoimmune diseases. The company’s research strategy focuses on the modulation of B-cell biology through novel antibody and small‐molecule agents. Since its founding in 2003, TG Therapeutics has built a diversified portfolio aimed at addressing unmet medical needs in oncology and immunology.

In December 2022, TG Therapeutics achieved its first commercial milestone when ublituximab-xiiy (marketed as Briumvi® in collaboration with Biogen) received U.S.